Description

Product Description

AGPV TFA is a synthetic tetrapeptide in trifluoroacetate salt form, designed for research on schistosome parasite infection prevention and host–parasite molecular interactions. This bioactive peptide consists of the amino acid sequence Ala-Gly-Pro-Val, representing a compact yet functionally rich molecular structure that enables selective modulation of parasitic mechanisms and immune responses in experimental systems.

Schistosomiasis, caused by Schistosoma spp., is a neglected tropical disease affecting over 200 million people globally. The complex life cycle and immune evasion strategies of these parasites make prevention particularly challenging. Peptide-based agents such as AGPV TFA are gaining attention as innovative bio-tools for interrupting parasite adhesion, invasion, and host immune modulation.

AGPV TFA functions through several potential mechanisms, including interfering with parasite proteases, blocking receptor-mediated attachment, and enhancing innate and adaptive immune activity. Its trifluoroacetate salt form enhances stability, solubility, and peptide handling, making it suitable for in vitro assays, animal infection models, and mechanistic immunology studies.

Research Applications

• Anti-parasitic agent — potential to prevent Schistosoma infection by disrupting parasite–host adhesion mechanisms.

• Immunomodulatory peptide — enhances host defense mechanisms and balances cytokine responses.

• Vaccine development — candidate adjuvant or peptide component for experimental anti-schistosomal vaccines.

• Host–pathogen interaction model — useful in studying parasite penetration and immune evasion pathways.

Overall, AGPV TFA represents a novel peptide-based research compound bridging immunology, parasitology, and peptide chemistry, offering a foundation for developing new therapeutic and prophylactic strategies against schistosomiasis and similar parasitic infections.

Product Specifications

Mechanism of Action

AGPV TFA operates through multi-pathway modulation of host–parasite biological interactions, reflecting the multifunctional nature of short peptides in biological systems.

1. Interference with Parasite–Host Adhesion

During infection, schistosome larvae (cercariae) utilize specific adhesion molecules to bind to host skin or epithelial tissues. AGPV TFA may act as a competitive inhibitor, mimicking host peptide motifs and disrupting parasite receptor binding, thereby reducing infection efficiency.

2. Protease Inhibition and Barrier Protection

The parasite releases proteolytic enzymes to degrade host tissue barriers. AGPV TFA is believed to interfere with cysteine or serine protease activity, thereby preserving tissue integrity and blocking parasite penetration.

3. Immunomodulation

AGPV TFA can modulate the immune microenvironment by enhancing Th1/Th2 balance, promoting macrophage activation, and supporting antigen presentation. This helps the host’s immune system recognize and respond more effectively to invading parasites.

4. Oxidative Stress and Inflammatory Regulation

Parasitic infection often leads to local oxidative stress. AGPV TFA has potential antioxidant effects, reducing cellular damage and supporting controlled inflammatory responses that limit parasite survival.

5. Vaccine Adjuvant Potential

Due to its immunogenicity and low cytotoxicity, AGPV TFA may serve as an adjuvant or component in multi-epitope vaccines, providing dual benefits—immune enhancement and parasite recognition modulation.

Through these combined mechanisms, AGPV TFA serves as a multifunctional peptide scaffold in parasitology and immunology research, supporting the development of next-generation anti-parasitic strategies.

Side Effects

AGPV TFA is intended for laboratory research use only, and its safety in humans or animals has not been fully evaluated. However, based on related short peptide analogs, expected properties include:

• Low cytotoxicity at standard in vitro concentrations.

• Mild immunogenicity possible with repeated exposure in animal models.

• Non-irritating and biocompatible when handled appropriately.

• Potential transient peptide sensitivity reactions in cell culture experiments.

Researchers should apply standard safety protocols when handling bioactive peptides and avoid direct human or veterinary exposure.

Disclaimer

AGPV TFA is supplied for research use only (RUO). Not for diagnostic, therapeutic, or clinical use. All data provided are for scientific reference and experimental planning purposes.

Keywords

AGPV TFA, AGPV trifluoroacetate, tetrapeptide TFA, antiparasitic peptide, schistosome infection prevention, host–parasite interaction, peptide immunomodulator, peptide vaccine adjuvant, protease inhibitor peptide, peptide drug research, parasitology research compound.

Shipping Guarantee

All peptide compounds are shipped under validated temperature-controlled conditions with full traceability and batch certification to maintain product integrity and stability during transit.

Transaction Guarantee

We provide verified analytical data (HPLC, MS), authenticity documentation, and global shipping assurance for all peptide products. Secure and compliant international transactions guaranteed.